Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth Medicare PPO Formulary Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy FID 00025343

    AmeriHealth Medicare PPO 2025 Formulary (Drug List)

    Customize your policy alerts

    Sign up for AmeriHealth Policy FID 00025343 alerts

    Get alerted when Policy FID 00025343 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the AmeriHealth Medicare PPO 2025 Formulary describing which prescription drugs are covered, applicable coverage restrictions (prior authorization, quantity limits, step therapy), and how members or prescribers can request exceptions or transition supplies. It applies to AmeriHealth Medicare PPO members and participating network pharmacies.

    Policy Summary
    PayerAmeriHealth
    PolicyAmeriHealth Medicare PPO 2025 Formulary (Drug List)
    Policy CodePolicy FID 00025343
    Change TypeNo material clinical or coverage changes in this revision.
    Effective Date10/17/2025
    Next Review DateN/A
    Key ActionObtain prior authorization from AmeriHealth Medicare PPO before dispensing drugs labeled 'PA' to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MonthlyFormulary updates
    72 hoursException decision
    30 daysMember notice (midyear)
    60 daysPossible refill after change
    Vaccines & ImmunoglobulinsMajor categories present

    Formulary Coverage & Application

    inv-01: Standard Formulary Coverage — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    ALL of the following

    • The drug is listed on the AmeriHealth formulary or a formulary exception has been approved.
    • The prescription is filled at an AmeriHealth Medicare PPO network pharmacy (or other network delivery channel allowed by the plan).
    • The drug is medically necessary for the member as determined by the prescriber and consistent with accepted standards of care.
    • Any applicable utilization management requirements (Prior Authorization, Step Therapy, Quantity Limits, Non-Extended Day Supply) are satisfied at the time of dispensing.

    inv-03: General formulary coverage logic — Coverage is agent-specific and subject to tier assignment, quantity limits (QL), and prior authorization (PA) where indicated.

    Policy Summary
    PayerAmeriHealth
    PolicyAmeriHealth Medicare PPO 2025 Formulary (Drug List)
    Policy CodePolicy FID 00025343
    Change TypeNo material clinical or coverage changes in this revision.
    Effective Date10/17/2025
    Next Review DateN/A
    Key ActionObtain prior authorization from AmeriHealth Medicare PPO before dispensing drugs labeled 'PA' to ensure coverage.
    SourceLink
    On This Page
    Formulary Coverage & ApplicationPrior Authorization, Step Therapy & Documentation RequirementsCodes, Flags & Quantity ExamplesStep Therapy Placement & NotesPer-Product Quantity Limits (selected examples)Formulary Site-of-Care NotesKey Terms & AbbreviationsFormulary Scope & StructureBiosimilar Substitution & Policy

    Coverage is agent-specific and subject to tier assignment, quantity limits (QL), and prior authorization (PA) where indicated.

    ALL of the following

    • Each formulary row reflects the drug, strength, formulation, tier, and any Requirements/Limits annotations (e.g., PA, QL, ST, NDS, NF).
    • Coverage availability and member cost-share are determined by the assigned formulary tier and any utilization controls shown in the Requirements/Limits column.
    • Non-Formulary (NF) drugs are not covered under the plan unless a formulary exception is approved; members may request exceptions per plan procedures.
    • When multiple formulations or strengths exist, utilization controls may vary by formulation; follow the specific row-level Requirements/Limits for coverage determinations.

    inv-04: Formulary tier and control application — Coverage and utilization controls as listed in the formulary table (by drug/formulation/strength).

    Coverage and utilization controls apply as listed in the formulary table (drug/formulation/strength specific).

    ALL of the following

    • Providers and pharmacies must follow the Requirements/Limits annotations shown for each drug (e.g., PA, QL, ST, NDS).
    • Prior Authorization (PA) must be obtained prior to dispensing when indicated; if PA is not obtained, the claim may be denied.
    • Quantity Limits (QL) restrict the maximum quantity covered per time period and are applied per the formulary row.
    • Step Therapy (ST) requires trial of specified agents prior to coverage of alternative agents when noted.

    inv-05: Coverage logic per formulary row — Formulary coverage with utilization management

    Formulary coverage is applied per row and may include utilization management annotations.

    ALL of the following

    • When a drug row includes multiple annotations (e.g., PA; QL; NDS), all listed controls apply concurrently unless otherwise noted in the plan guidance.
    • Non-Extended Day Supply (NDS) indicates limits on days supplied (commonly applied to opioids) and may be enforced at retail and mail order per plan policy.
    • For opioid medications, opioid-specific limits (NDS, QL, PA) described in the formulary and plan opioid policy must be followed for dispensing and refills.

    inv-06: Formulary utilization management — Coverage and utilization management determined by formulary annotations; drugs listed may be covered subject to listed tier, PA, ST, and QL.

    Coverage and utilization management are determined by formulary annotations; drugs listed may be covered subject to listed tier, PA, ST, and QL.

    ALL of the following

    • Members and providers may request a formulary exception for Non-Formulary (NF) drugs; exceptions are evaluated per AmeriHealth exception procedures and medical necessity criteria.
    • Formulary designations (covered tiers, NF) and annotations (PA, QL, ST, NDS) are binding for benefit determination unless an approved exception or other coverage policy applies.
    • Pharmacies should verify the member’s specific plan benefit and any active authorizations prior to dispensing to avoid claim denials and member liability.

    inv-07: COVERAGE CRITERIA — Non-Formulary (NF) drugs are not covered under the plan unless a formulary exception is approved.

    Transition and Emergency Supply — temporary coverage allowances when a member needs immediate access to medication.

    ANY of the following

    • Transition supply: When a member is newly enrolled or when a drug’s formulary status changes, the plan may permit a one-time transition supply (up to a time-limited quantity) to allow the member to continue therapy while PA/ST or a formulary exception is obtained; the exact allowed quantity and duration follow plan transition rules.
    • Emergency supply: Pharmacies may dispense a limited emergency supply when a delay in obtaining prior authorization, a refill authorization, or access to a network pharmacy would result in an interruption of clinically necessary therapy; emergency fills are limited to the lesser of the prescriber-intended quantity or a plan-defined short-term supply (commonly a 72-hour to 30-day supply depending on the drug class and plan rules).
    • Opioid-specific emergency/transition rules: For opioid medications, Non-Extended Day Supply (NDS) and opioid quantity limits still apply; emergency supplies must comply with opioid safety and dispensing limits defined by the plan and applicable regulations.
    • Documentation and follow-up: Emergency or transition supplies should be accompanied by documentation of the reason for the supply (e.g., new enrollment, pending PA, urgent need). Providers must complete any required PA or submit needed clinical information within the plan-specified timeframe to continue coverage beyond the transition/emergency supply period.
    • Member notification and cost-sharing: Members should be informed that transition or emergency supplies are temporary; standard cost-sharing applies unless otherwise specified by the plan, and ongoing therapy requires meeting applicable utilization management requirements.

    inv-08: COVERAGE CRITERIA — Drugs labeled 'NF' are designated as not formulary in this listing (examples noted).

    Drugs labeled 'NF' are designated as not formulary in this listing (examples noted).

    ALL of the following

    • An NF designation means the drug is not included in the formulary and is not covered unless an exception is granted following the plan’s exception process.
    • Members and prescribers may request a formulary exception when a medically appropriate alternative is not available or has failed; exception requests must include clinical justification and supporting documentation.

    inv-16: COVERAGE CRITERIA — No explicit 'Not Medically Necessary' (NMN) determinations present in these chunks.

    No explicit 'Not Medically Necessary' (NMN) determinations are present in these formulary chunks. Coverage determinations rely on formulary status and utilization controls.

    ALL of the following

    • Where a service or drug is not listed as covered (NF) or exceeds utilization controls, providers may submit supporting clinical documentation for review under the plan’s exception or appeal processes.
    • Standard medical necessity and benefit-check processes apply for requests outside formulary listings; decisions will be made per AmeriHealth clinical and coverage policies.

    Prior Authorization, Step Therapy & Documentation Requirements

    Prior Authorization

    Obtain Prior Authorization for PA‑flagged drugs

    Certain drugs require prior authorization; providers must obtain approval from AmeriHealth Medicare PPO before the prescription will be covered.

    Prior Authorization

    Get PA before dispensing

    Prior authorization is required for listed drugs; members or providers must secure prior approval before filling prescriptions or coverage may be denied.

    Prior Authorization

    PA required for select hepatitis C agents (EPCLUSA, MAVYRET)

    Drugs marked 'PA' and specific hepatitis C agents (e.g., EPCLUSA, MAVYRET) include PA flags and QL entries; prescribers must follow the PA process before these products will be covered.

    • EPCLUSA entries show 'PA; QL (168 EA per 365 days)' and 'PA; QL (84 EA per 365 days).
    • MAVYRET entries are marked 'PA' with QL (560 EA per 365 days) for packets and QL (336 EA per 365 days) for tablets.
    Prior Authorization

    PA required for many oral oncology drugs

    Many oral oncology agents in the formulary are designated 'PA'; prescribers must obtain prior authorization for these antineoplastic drugs prior to coverage.

    • Examples include ALECENSA, ALUNBRIG, AYVAKIT (PA; some with QL), and multiple other oral antineoplastics shown with 'PA'.
    Step Therapy

    Follow Step Therapy when 'ST' is indicated

    Some drugs are subject to step therapy (ST); members must try specified alternative drugs first before coverage of a non‑preferred drug is provided.

    • Where products are annotated 'ST' the plan requires trial of preferred agent(s) before covering the listed product.
    Step Therapy

    Document prior therapy for ST exceptions

    Step Therapy may require trying specified alternative drug(s) first (Drug A before Drug B) — the prescriber must document prior steps have been tried and failed or were intolerable before the plan will cover the next‑step drug.

    • Plan documentation and prior therapy evidence should be provided when requesting coverage of the next‑step agent.
    Denial Risk

    Coverage may be denied without PA

    Failure to obtain required prior authorization may result in AmeriHealth Medicare PPO not covering the drug.

    Denial Risk

    PA not obtained → denial risk

    If Prior Authorization (PA) is required and not obtained, the plan may deny coverage for the drug — prescribers must submit PA before dispensing to avoid denial.

    Note

    See page 6 for symbol legend

    Consult the formulary legend on page 6 for definitions of symbols and abbreviations used in the Requirements/Limits column (e.g., NF, PA, QL, ST, numeric tiers).

    • Refer to page 6 of the formulary for the full symbol/abbreviation legend.
    Documentation Required

    Provide prescriber supporting statement for exceptions

    A prescriber's supporting statement is required when requesting a formulary or tiering exception; standard decision timeframe is generally 72 hours and expedited requests may be decided within 24 hours.

    • Prescriber must explain medical reasons for the exception; plan generally decides within 72 hours of receiving the supporting statement.
    • If expedited, the plan must decide within 24 hours after receiving the prescriber's supporting statement.
    Documentation Required

    Follow the Requirements/Limits field on the formulary

    Providers must follow the Requirements/Limits column on the formulary for each drug; entries indicate if PA, QL, ST, NDS, or NF apply and determine what documentation or authorization is needed.

    • Use the Requirements/Limits field on the formulary row to identify necessary prior authorization, quantity limits, or step therapy requirements.
    Documentation Required

    Submit PA with required documentation for PA‑flagged strengths

    Products flagged 'PA' require prior authorization; formulary rows list strength‑level PA flags that prescribers must follow when submitting authorization requests.

    • Examples in the table show PA adjacent to specific strengths and formulations (e.g., armodafinil entries labeled 'PA; QL').
    Billing Rule

    Adhere to Quantity Limits (QL) or request exception

    Prescriptions that exceed the listed quantity limit (QL) may be denied or require additional review; providers should adhere to the specified QL or request an exception with supporting documentation.

    • Examples of QLs include QL (30 EA per 30 days), QL (60 EA per 30 days), QL (180 EA per 30 days); exceeding these limits may trigger coverage limits or denial.
    Denial Risk

    PA/QL enforcement may cause denial

    Claims for drugs noted with 'PA' and for prescriptions exceeding specified QLs are subject to denial if prior authorization is not obtained or quantity limits are exceeded.

    Codes, Flags & Quantity Examples

    Formulation / Identifiersmixed
    albuterol sulfate HFA inhalation aerosol 108 mcg/actNF; QL (13.4 GM per 30 days)
    albuterol sulfate nebulization solution 2.5 mg/3mlTier 2; PA; QL (13.4 GM per 30 days)
    arformoterol tartrate inhalation nebulization solutionTier 4; PA; QL (13.4 GM per 30 days)
    Formulary flags & Quantity Limitsmixed
    morphine sulfate (concentrate) oral solution 100 mg/5mlTier 2; NDS; QL (150 ML per 30 days)
    morphine sulfate oral solutionNDS; QL (1000 ML per 30 days)
    morphine sulfate ER oral tablet extended release 15-100 mgNDS; QL (90 EA per 30 days) or NDS; QL (180 EA per 30 days) depending on strength
    oxycodone HCl oral concentrate 100 mg/5mlNDS; QL (180 ML per 30 days)
    oxycodone HCl oral solutionNDS; QL (900 ML per 30 days)
    oxycodone HCl oral tabletNDS; QL (180 EA per 30 days)
    methadone HCl oral tabletPA; NDS
    Formulation & QL entries (partial)mixed
    diazepam intensol oral concentrateQL (240 ML per 30 days)
    diazepam oral solution 5 mg/5mlQL (1200 ML per 30 days)
    eszopiclone oral tablet 1-3 mgPA; QL (30 EA per 30 days) for 3 mg; QL (30 EA per 30 days) for 1-2 mg
    Drug listing (no procedure codes)mixed
    aprepitant oral capsule 40/80/125 mgPA; QL (4-12 EA per 30 days depending on strength)
    budesonide inhalation suspensionPA; QL (120 ML per 30 days)
    BREZTRI AEROSPHERE INHALATION AEROSOLQL (23.6 GM per 28 days)
    inv-23: Glipizide ER per prescription example — 60 per prescription
    Glipizide ER per prescription example — 60 per prescription
    inv-24: Opioid supply limit (retail/mail) — 30-day supply
    Opioid supply limit (retail/mail) — 30-day supply
    inv-25: Quantity limits examples — Examples include QL (30 EA per 30 days), QL (168 EA per 365 days), QL (560 EA per 365 days)
    Quantity limits examples — Examples include QL (30 EA per 30 days), QL (168 EA per 365 days), QL (560 EA per 365 days)
    inv-29: Common QL thresholds — Examples include 30 EA per 30 days, 60 EA per 30 days, 240 mL per 30 days
    Common QL thresholds — Examples include 30 EA per 30 days, 60 EA per 30 days, 240 mL per 30 days

    Step Therapy Placement & Notes

    Policy PointDescription
    Step therapy applies when plan requires trying certain drugs first
    Members must try specified alternative (preferred) agent(s) before coverage will be provided for a non-preferred drug; if the preferred agent is ineffective or not tolerated, coverage for the next-step drug will be considered
    See the formulary Requirements/Limits column for entries marked 'ST' to identify which products have step therapy
    Examples (product/presentation)Formulary annotation
    TOPAMAX (topiramate) — various oral forms (sprinkle, ER, tablets)
    XCOPRI (cenobamate) — therapy packs and tablets
    VIGAFYDE oral solution — listed with ST
    Savella and Fanapt (as noted elsewhere in formulary) — marked ST in entries
    ProductFormulary annotation / requirement
    SANCUSO transdermal patch
    Requirements/Limits: ST; QL (4 EA per 28 days) — step therapy required prior to coverage
    Tier noteInterpretation
    Numeric tiers (1–5) shown adjacent to many products
    Tier placement indicates relative formulary placement (preferred vs non-preferred) but the excerpt does not specify multi-step sequences tied to tier numbers
    Some high-cost or specialty agents are placed on higher tiers (3–5) and may be subject to PA or step requirements per the Requirements/Limits column

    Per-Product Quantity Limits (selected examples)

    Glipizide ER 10 mg — example limit
    Glipizide ER 10 mg (example)60 per prescription
    Source noteListed as plan example in Restrictions and Limits text
    ApplicationQuantity limit shown in Requirements/Limits column; applies per prescription unless otherwise noted
    Opioid class supply limit
    Opioids (class rule) — retail/mail30 (day) supply limit
    Long‑term care31 days
    OptumRx Home DeliveryRequires 75% used before refill
    EPCLUSA / MAVYRET QL examples
    EPCLUSA (oral packet/tablet)QL (84/168 EA per 365 days) depending on strength; PA indicated for some strengths
    MAVYRET (oral packet/tablet)QL (560 EA per 365 days) for packet; QL (336 EA per 365 days) for tablet; marked PA
    NotesQuantity limits and PA flags vary by strength and form; refer to Requirements/Limits column
    PAXLOVID therapy pack limits
    PAXLOVID therapy packs — examplesQL (20 EA per 5 days; 11 EA per 5 days; 30 EA per 5 days) depending on pack
    ContextTherapy‑pack QLs specified per course (5‑day pack) in Requirements/Limits
    ActionFollow pack‑specific QL when dispensing Paxlovid therapy packs
    BRAFTOVI quantity limit
    BRAFTOVI180 per 30 days
    SourceListed QL for BRAFTOVI in formulary rows
    AYVAKIT quantity limit
    AYVAKIT30 EA per 30 days
    PA flagAYVAKIT listed as PA; QL applies as shown
    PROMACTA (eltrombopag) limits
    PROMACTA oral tablet 12.5 mg360 per 30 days
    Related strengthsPROMACTA 25 mg = 180 per 30 days; 75 mg = 60 per 30 days
    REPATHA SURECLICK limit
    REPATHA SURECLICK auto-injector3 per month
    FormulationSubcutaneous auto-injector presentation; QL listed in Requirements/Limits
    Hydromorphone quantity limits
    Hydromorphone ER / oral tablet120 EA per 30 days
    Hydromorphone liquidQL (1500 mL per 30 days) for some liquid forms
    Pregabalin quantity limits
    Pregabalin (various strengths)90 EA per 30 days (typical QL)
    Higher strengthsSome strengths (225/300 mg) show QL 60 EA per 30 days
    VALTOCO limit
    VALTOCO nasal liquid (all strengths)10 EA per 30 days
    PA flagVALTOCO entries show PA plus QL of 10 EA per 30 days
    CGRP inhibitor limits (AIMOVIG / EMGALITY)
    AIMOVIG 70 mg2 per 30 days (QL)
    EMGALITY prefilled/auto-injectorQL indicated as 3 or 2 (depends on presentation: 3 mL per 30 days or 2 mL per 28 days)
    NURTEC quantity limit
    NURTEC oral tablet dispersible18 per 30 days
    PA flagNURTEC listed as PA; QL (18 EA per 30 days)
    XYREM limit
    XYREM ORAL SOLUTION540 mL per 30 days
    PA flagXYREM listed as PA; QL (540 ML per 30 days)
    Lorazepam limits
    Lorazepam / lorazepam tablets90–150 EA per 30 days depending on strength
    Lorazepam Intensol oral concentrateQL (150 mL per 30 days)
    Aprepitant quantity limits
    Aprepitant oral capsule 125 mgQL (4 EA per 30 days)
    Aprepitant 40/80 mgQL (8 EA per 30 days); combination 80 & 125 mg = QL (12 EA per 30 days)
    Pantoprazole packet limit
    Pantoprazole sodium oral packetQL (60 EA per 30 days)
    Packet/tablet consistencyBoth packet and tablet formulations show QL (60 EA per 30 days) where listed
    LINZESS and related QLs
    LINZESS oral capsuleQL (30 EA per 30 days)
    LubiprostoneQL (60 EA per 30 days)
    BREZTRI AEROSPHERE limit
    BREZTRI AEROSPHERE inhalation aerosolQL (23.6 GM per 28 days)
    Inhalation QL contextInhalation products often list mass (GM) per 28 or 30 days as QL

    Formulary Site-of-Care Notes

    Documentation Required

    Document site‑of‑care for outpatient/home formulations

    Many agents listed include formulations intended for outpatient/home use (oral tablets/capsules, transdermal patches, subcutaneous auto‑injectors); ensure appropriate site‑of‑care documentation when submitting claims or prior authorization requests.

    • Examples include oral tablets, transdermal patches, and subcutaneous auto‑injectors intended for home administration.

    Key Terms & Abbreviations

    Definition: Prior Authorization
    Prior Authorization (PA)Plan approval required before filling certain drugs or coverage may be denied.
    Effect of no PAFailure to obtain PA may result in the plan not covering the drug
    Where listedPA is indicated in the Requirements/Limits column next to specific drug entries
    Definition: Quantity Limits
    Quantity Limits (QL)Plan limits the amount of drug covered per prescription (example: 60 per prescription for Glipizide ER 10 mg).
    ApplicationSpecified as 'QL (N EA per 30 days)' or similar in Requirements/Limits column
    EnforcementDispensed quantity must not exceed listed QL or claim may be limited/denied
    Definition: Step Therapy
    Step Therapy (ST)Member must try specified drugs first before the plan will cover alternative drugs.
    How it appearsShown as 'ST' in Requirements/Limits column for applicable products
    Evidence neededPrescriber must document prior trial and failure/intolerance of required agent(s) per step rules
    Definition: Non‑Extended Day Supply (NDS)
    Non-Extended Day Supply (NDS)Limits opioid prescriptions to a 30-day supply for retail and mail order; long-term care 31 days; home delivery rules apply (OptumRx requires 75% used before refill).
    Applies toAll prescription fills for opioid medications unless otherwise specified
    Referenced locationNDS and opioid limits described in Requirements/Limits guidance in formulary overview
    Definition: Non‑Formulary (NF)
    Non‑Formulary (NF)Drug is not covered under the plan; a Formulary Exception may be requested.
    How shownMarked 'NF' in Requirements/Limits column for listed drug entries
    Exception processMembers/providers may request a formulary exception per the plan's exception procedures
    Symbols & abbreviations
    Symbols & abbreviations legendMeanings of NF, PA, QL, numeric tiers (and other symbols) are defined on page 6 of the full formulary.
    Where to findRefer to page 6 for full legend and symbol definitions
    UsageFormulary rows use these symbols in the Requirements/Limits column to indicate controls

    Formulary Scope & Structure

    This formulary groups medications by medical condition and lists each drug line with a Tier and Requirements/Limits column. Requirements and limits include flags such as PA (prior authorization), QL (quantity limits), ST (step therapy), and NF (non‑formulary). The document therefore defines which drugs are covered and indicates any utilization management (e.g., PA or QL) that must be satisfied for coverage.

    Biosimilar Substitution & Policy

    Billing Rule

    Biosimilar substitution and tier changes — document exceptions if needed

    The plan may immediately replace an original biological product with a biosimilar (including interchangeable biosimilars) and may move the original biologic to a different tier; providers may request an exception to continue the original product.

    • If a biosimilar is added, the plan can substitute or change tiering for the original biologic without advance notice; prescribers can request an exception to maintain the original product.